PartnershipJul 21, 2026, 07:41 AM
PolyPid Partners with Azurity for D-PLEX100; Up to $320M+ Potential
AI Summary
PolyPid Ltd. announced an exclusive partnership with Azurity Pharmaceuticals for the commercialization of its product D-PLEX100 in the United States and Canada. Under the agreement, PolyPid will receive an upfront payment of $15 million and an additional $15 million upon U.S. FDA acceptance of the New Drug Application, expected in August 2026. The company is also eligible for up to $300 million in additional milestone payments and tiered royalties from mid-teen to mid-twenties percentages. PolyPid will manufacture and supply the product, while Azurity will fund potential label expansion studies.
Key Highlights
- PolyPid entered an exclusive License and Supply Agreement with Azurity Pharmaceuticals for D-PLEX100 in the U.S. and Canada.
- PolyPid to receive an upfront payment of $15 million.
- An additional $15 million milestone payment is due upon U.S. FDA acceptance of the NDA, expected August 2026.
- Eligible for up to approximately $300 million in additional regulatory, development, and sales-based milestone payments.
- PolyPid will receive tiered royalties ranging from mid-teen to mid-twenties percentages.
- PolyPid will manufacture and supply D-PLEX100 to Azurity.
- Azurity will fund clinical development for potential label expansion beyond abdominal SSI indications.
- PolyPid retains global commercial rights outside the U.S. and Canada, and full ownership of its platforms.
Price Impact
More from PYPD